Top

Published in:

01-06-2018 | Review Article

A new era in headache treatment

Authors: Michail Vikelis, Konstantinos C. Spingos, Alan M. Rapoport

Published in: Neurological Sciences | Special Issue 1/2018

Abstract

Primary headache disorders, such as migraine and cluster headache, are common and often debilitating. When preventive therapy is needed, several oral medications are used. Patients tend to have poor adherence and persistence on their preventive therapy. The introduction of treatments blocking calcitonin gene-related peptide (CGRP) is anticipated to begin a new era in migraine preventive treatment. In addition, non-triptan serotonin receptor agonists, newer delivery systems for older therapies, and innovative devices represent other exciting advances in acute and preventive migraine and cluster treatment and shall also be discussed in this review.

Global Burden of Disease Study (2013) Collaborators (2015) Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386:743–800

Leonardi M, Raggi A (2013) Burden of migraine: international perspectives. Neurol Sci 34(Suppl 1):S117–S118PubMed

Lipton RB, Clin SWF (1998) Migraine headaches: epidemiology and comorbidity. Neurosci 5(1):2–9

Stewart WF, Lipton RB, Celentano DD, Reed ML (1992) Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA 267:64–69PubMed

Maasumi K, Tepper SJ, Kriegler JS (2017) Menstrual migraine and treatment options: review. Headache 57:194–208PubMed

Burch RC, Loder S, Loder E, Smitherman TA (2015) The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. Headache 55:21–34PubMed

Lipton RB, Bigal ME (2005) Migraine: epidemiology, impact, and risk factors for progression. Headache 45(Suppl 1):S3–s13PubMed

Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N, Gillard P, Hansen RN, Devine EB (2017) Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia 37(5):470–485

Cameron C, Kelly S, Hsieh SC, Murphy M, Chen L, Kotb A, Peterson J, Coyle D, Skidmore B, Gomes T, Clifford T, Wells G (2015) Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache 55(Suppl 4):221–235PubMed

10.

Rizzoli PB (2012) Acute and preventive treatment of migraine. Continuum (Minneap Minn) 18(4):764–782

11.

Robbins MS, Starling AJ, Pringsheim TM, Becker WJ, Schwedt TJ (2016) Treatment of cluster headache: the American Headache Society Evidence-based guidelines. Headache 56(7):1093–1106PubMed

12.

Maasumi K, Tepper SJ, Rapoport AM (2017) New treatments for headache. Neurol Sci 38(Suppl 1):S145–S156

13.

Edvinsson L, Chan KY, Eftekhari S, Nilsson E, de Vries R, Saveland H, Dirven CM, Danser AH (2010) Effect of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries. Cephalalgia 30(10):1233–1240PubMed

14.

Kageneck C, Nixdorf-Bergweiler BE, Messlinger K, Fischer MJ (2014) Release of CGRP from mouse brainstem slices indicates central inhibitory effect of triptans and kynurenate. J Headache Pain 15:7PubMedPubMedCentral

15.

Russo AF (2015) Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu Rev Pharmacol Toxicol 55:533–552PubMed

16.

Goadsby PJ, Edvinsson L, Ekman R (1990) Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28:183–187PubMed

17.

Ho TW, Edvinsson L, Goadsby PJ (2010) CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 6:573–582PubMed

18.

Asghar MS, Hansen AE, Amin FM, van der Geest RJ, Koning P, Larsson HB, Olesen J, Ashina M (2011) Evidence for a vascular factor in migraine. Ann Neurol 69:635–645PubMed

19.

Petersen KA, Lassen LH, Birk S, Lesko L, Olesen J (2005) BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation. Clin Pharmacol Ther 77:202–213PubMed

20.

MaassenVanDenBrink A (2010) Effect of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries. Cephalalgia 30:1233–1240PubMed

21.

Yao G, Yu T, Han X, Mao X, Li B (2013) Therapeutic effects and safety of olcegepant and telcagepant for migraine: a meta-analysis. Neural Regen Res 8:938–947PubMedPubMedCentral

22.

Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM (2004) Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350:1104–1110PubMed

23.

Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ, Lines CR, Rapoport AM (2008) Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 70:1304–1312PubMed

24.

Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, Lei-bensperger H, Froman S, Assaid C, Lines C, Koppen H, Winner PK (2008) Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 372:2115–2123PubMed

25.

Connor KM, Shapiro RE, Diener HC, Lucas S, Kost J, Fan X, Fei K, Assaid C, Lines C, Ho TW (2009) Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology 73:970–977PubMedPubMedCentral

26.

Cui XP, Ye JX, Lin H, Mu JS, Lin M (2015) Efficacy, safety, and tolerability of telcagepant in the treatment of acute migraine: a meta-analysis. Pain Pract 15:124–131PubMed

27.

Ho TW, Connor KM, Zhang Y, Pearlman E, Koppenhaver J, Fan X, Lines C, Edvinsson L, Goadsby PJ, Michelson D (2014) Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology 83:958–966PubMed

28.

Ho TW, Ho AP, Ge YJ, Assaid C, Gottwald R, MacGregor EA, Mannix LK, van Oosterhout WP, Koppenhaver J, Lines C, Ferrari MD, Michelson D (2016) Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine. Cephalalgia 36:148–161PubMed

29.

Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ (2014) BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia 34:114–125PubMed

30.

Diener HC, Barbanti P, Dahlof C, Reuter U, Habeck J, Podhorna J (2011) BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia 31:573–584PubMed

31.

Voss T, Lipton RB, Dodick DW, Dupre N, Ge JY, Bachman R, Assaid C, Aurora SK, Michelson D (2016) A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia 36:887–898PubMed

32.

Wang W, Wang EQ, Balthasar JP (2008) Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 84:548–558PubMed

33.

Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA (2017) A controlled trial of erenumab for episodic migraine. N Engl J Med 377(22):2123–2132PubMed

34.

Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377(22):2113–2122PubMed

35.

Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, Saper J, Cady R, Chon Y, Dietrich J, Lenz R (2016) Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 15:382–390PubMed

36.

Shi L, Lehto SG, Zhu DX, Sun H, Zhang J, Smith BP, Immke DC, Wild KD, Xu C (2016) Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor. J Pharmacol Exp Ther 356:223–231PubMed

37.

Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, Wilks K, Kudrow D, Kroll R, Kohrman B, Bargar R, Hirman J, Smith J (2014) Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol 13:1100–1107PubMed

38.

Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS (2014) Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol 13:885–892

39.

Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R, Loupe PS, Burstein R, Newman LC, Lipton RB (2015) Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14:1081–1090PubMed

40.

Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, Palmer K, Picard H, Mikol DD, Lenz RA (2018) ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia Jan 1:333102418759786. https://doi.org/10.1177/0333102418759786 CrossRef

41.

Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, Winner P, Leonardi D, Mikol D, Lenz R (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomized, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16(6):425–434PubMed

42.

http://investor.alderbio.com/news-releases/news-release-details/alder-biopharmaceuticals-announces-positive-eptinezumab-phase-3. Last accessed online on 02/10/2018

43.

Skljarevski V, Oakes TM, Zhang Q, Ferguson MB, Martinez J, Camporeale A, Johnson KW, Shan Q, Carter J, Schacht A, Goadsby PJ, Dodick DW (2017) Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial. JAMA Neurol Dec 18.

44.

Oakes TMM, Skljarevsuki V, Zhang Q, Kielbasa W, Hodsdon ME, Detke HC, Camporeale A, Saper JR (2018) Safety of galcanezumab in patients with episodic migraine: a randomized placebo-controlled dose-ranging phase 2b study. Cephalalgia 1:333102417747230

45.

Vollesen A, Haulund L, Ashina Μ (2017) PACAP38: emerging drug target in migraine and cluster headache. Headache 57:56–63PubMed

46.

Ferrari MD, Farkkila M, Reuter U, Pilgrim A, Davis C, Krauss M, Diener HC (2010) Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan—a randomised proof-of-concept trial. Cephalalgia 30:1170–1178PubMed

47.

Farkkila M, Diener HC, Geraud G, Lainez M, Schoenen J, Harner N, Pilgrim A, Reuter U (2012) Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol 11:405–413PubMed

48.

https://www.medscape.com/viewarticle/883797 last accessed on 5/3/2018

49.

Cady RK, Munjal S, Cady RJ, Manley HR, Brand-Schieber E (2017) Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine. J Headache Pain 18:17PubMedPubMedCentral

50.

Spierings EL, Brandes JL, Kudrow DB, Weintraub J, Schmidt PC, Kellerman DJ, Tepper SJ (2017) Randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the safety and efficacy of ADAM zolmitriptan for the acute treatment of migraine. Cephalalgia Jan 1:333102417737765

51.

Puledda F, Goadsby PJ (2016) Current approaches to neuromodulation in primary headaches: focus on vagal nerve and sphenopalatine ganglion stimulation. Curr Pain Headache Rep 20:47PubMedPubMedCentral

52.

Schwedt TJ, Vargas B (2015) Neurostimulation for treatment of migraine and cluster headache. Pain Med 16:1827–1834PubMedPubMedCentral

53.

Clarke BM, Upton AR, Kamath MV, Al-Harbi T, Castellanos CM (2006) Transcranial magnetic stimulation for migraine: clinical effects. J Headache Pain 7:341–346PubMedPubMedCentral

54.

Lipton RB, Dodick DW, Silberstein SD, Saper JR, Aurora SK, Pearlman SH, Fischell RE, Ruppel PL, Goadsby PJ (2010) Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol 9:373–380PubMed

55.

Brighina F, Piazza A, Vitello G, Aloisio A, Palermo A, Daniele O, Fierro B (2004) rTMS of the prefrontal cortex in the treatment of chronic migraine: a pilot study. J Neurol Sci 227:67–71PubMed

56.

Conforto AB, Jr AE, Goncalves AL, Mercante JP, Guendler VZ, Ferreira JR, Kirschner CC, Peres MF (2014) Randomized, proof-of-principle clinical trial of active transcranial magnetic stimulation in chronic migraine. Cephalalgia 34:464–472PubMed

57.

Misra UK, Kalita J, Bhoi SK (2013) High-rate repetitive transcranial magnetic stimulation in migraine prophylaxis: a randomized, placebo-controlled study. J Neurol 260:2793–2801PubMed

58.

Teepker M, Hotzel J, Timmesfeld N, Reis J, Mylius V, Haag A, Oertel WH, Rosenow F, Schepelmann K (2010) Low-frequency rTMS of the vertex in the prophylactic treatment of migraine. Cephalalgia 30:137–144PubMed

59.

Tfelt-Hansen PC (2010) History of migraine with aura and cortical spreading depression from 1941 and onwards. Cephalalgia 30(7):780–792PubMed

60.

Bhola R, Kinsella E, Giffin N, Lipscombe S, Ahmed F, Weatherall M, Goadsby PJ (2015) Single-pulse transcranial magnetic stimulation (sTMS) for the acute treatment of migraine: evaluation of outcome data for the UK post market pilot program. J Headache Pain 16:535PubMed

61.

Silberstein SD, Dodick DW, Starling AJ, Tepper S (2017) A multicenter, prospective, single arm, open label, post-market, observational study to evaluate the use of sTMS in reduction of migraine headache (ESPOUSE Study) S52.004. Neurology 88 (16 Supplement)

62.

Magis D, Sava S, d’Elia TS, Baschi R, Schoenen J (2013) Safety and patients’ satisfaction of transcutaneous supraorbital neurostimulation (tSNS) with the Cefaly(R) device in headache treatment: a survey of 2,313 headache sufferers in the general population. J Headache Pain 14:95PubMedPubMedCentral

63.

Schoenen J, Vandersmissen B, Jeangette S, Herroelen L, Van-denheede M, Gerard P, Magis D (2013) Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology 80:697–704PubMed

64.

Riederer F, Penning S, Schoenen J (2015) Transcutaneous supraorbital nerve stimulation (t-SNS) with the Cefaly(R) device for migraine prevention: a review of the available data. Pain Ther 4:135–147PubMedCentral

65.

Vikelis M, Dermitzakis EV, Spingos KC, Vasiliadis GG, Vlachos GS, Kararizou E (2017) Clinical experience with transcutaneous supraorbital nerve stimulation in patients with refractory migraine or with migraine and intolerance to topiramate: a prospective exploratory clinical study. BMC Neurol 17:97PubMedPubMedCentral

66.

Oshinsky ML, Murphy AL, Jr HH, Cooper M, Simon BJ (2014) Noninvasive vagus nerve stimulation as treatment for trigeminal allodynia. Pain 155:1037–1042PubMedPubMedCentral

67.

Kinfe TM, Pintea B, Muhammad S, Zaremba S, Roeske S, Simon BJ, Vatter H (2015) Cervical non-invasive vagus nerve stimulation (nVNS) for preventive and acute treatment of episodic and chronic migraine and migraine-associated sleep disturbance: a prospective observational cohort study. J Headache Pain 16:101PubMedPubMedCentral

68.

Barbanti P, Grazzi L, Egeo G, Padovan AM, Liebler E, Bussone G (2015) Non-invasive vagus nerve stimulation for acute treatment of high-frequency and chronic migraine: an open-label study. J Headache Pain 16:61PubMedPubMedCentral

69.

Goadsby PJ, Grosberg BM, Mauskop A, Cady R, Simmons KA (2014) Effect of noninvasive vagus nerve stimulation on acute migraine: an open-label pilot study. Cephalalgia 34:986–993PubMed

70.

Grazzi L, Egeo G, Calhoun AH, McClure CK, Liebler E, Barbanti P (2016) Non-invasive vagus nerve stimulation (nVNS) as mini-prophylaxis for menstrual/menstrually related migraine: an open-label study. J Headache Pain 17:91PubMedPubMedCentral

71.

Silberstein SD, Calhoun AH, Lipton RB, Grosberg BM, Cady RK, Dorlas S, Simmons KA, Mullin C, Liebler EJ, Goadsby PJ, Saper JR (2016) Chronic migraine headache prevention with noninvasive vagus nerve stimulation: the EVENT study. Neurology 87:529–538PubMedPubMedCentral

72.

Nesbitt AD, Marin JC, Tompkins E, Ruttledge MH, Goadsby PJ (2015) Initial use of a novel noninvasive vagus nerve stimulator for cluster headache treatment. Neurology 84:1249–1253PubMed

73.

Gaul C, Diener HC, Silver N, Magis D, Reuter U, Andersson A, Liebler EJ, Straube A (2016) Non-invasive vagus nerve stimulation for prevention and acute treatment of chronic cluster headache (PREVA): a randomised controlled study. Cephalalgia 36:534–546PubMed

74.

Gaul C, Magis D, Liebler E, Straube A (2017) Effects of non-invasive vagus nerve stimulation on attack frequency over time and expanded response rates in patients with chronic cluster headache: a post hoc analysis of the randomised, controlled PREVA study. J Headache Pain 18(1):22PubMedPubMedCentral

75.

Silberstein SD, Mechtler LL, Kudrow DB, Calhoun AH, McClure C, Saper JR, Liebler EJ, Rubenstein Engel E, Tepper SJ (2016) Non-invasive vagus nerve stimulation for the acute treatment of cluster headache: findings from the randomized, double-blind, sham-controlled ACT1 study. Headache 56:1317–1332PubMedPubMedCentral

76.

Black RD, Rogers LL, Ade KK, Nicoletto HA, Adkins HD, Laskowitz DT (2016) Non-invasive neuromodulation using time-varying caloric vestibular stimulation. IEEE J Transl Eng Health Med 4:2000310PubMed

77.

Wilkinson D, Ade KK, Rogers LL, Attix DK, Kuchibhatla M, Slade MD, Smith LL, Poynter KP, Laskowitz DT, Freeman MC, Hoffer ME, Saper JR, Scott DL, Sakel M, Calhoun AH, Black RD (2017) Preventing episodic migraine with caloric vestibular stimulation: a randomized controlled trial. Headache 57(7):1065–1087PubMed

78.

Schytz HW, Barlose M, Guo S, Selb J, Caparso A, Jensen R, Ashina M (2013) Experimental activation of the sphenopalatine ganglion provokes cluster-like attacks in humans. Cephalalgia 33:831–841PubMed

79.

Schoenen J, Jensen RH, Lanteri-Minet M, Lainez MJ, Gaul C, Goodman AM, Caparso A, May A (2013) Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment. Pathway CH-1: a randomized, sham-controlled study. Cephalalgia 33:816–830PubMedPubMedCentral

80.

Ansarinia M, Rezai A, Tepper SJ, Steiner CP, Stump J, Stanton-Hicks M, Machado A, Narouze S (2010) Electrical stimulation of sphenopalatine ganglion for acute treatment of cluster headaches. Headache 50:1164–1174PubMed

81.

Barloese MC, Jurgens TP, May A, Lainez JM, Schoenen J, Gaul C, Goodman AM, Caparso A, Jensen RH (2016) Cluster headache attack remission with sphenopalatine ganglion stimulation: experiences in chronic cluster headache patients through 24 months. J Headache Pain 17:67PubMedPubMedCentral

82.

Barloese M, Petersen A, Stude P, Jürgens T, Jensen RH, Saper MA, JR DDW, Silberstein SD, McCarville S, Sun M (2018) Sphenopalatine ganglion stimulation for cluster headache, results from a large, open-label European registry. J Headache Pain 19(1):6PubMedPubMedCentral

83.

Goadsby PJ (2011) Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia 31:271–228PubMedPubMedCentral

84.

Silberstein SD, Dodick DW, Saper J, Huh B, Slavin KV, Sharan A, Reed K, Narouze S, Mogilner A, Goldstein J, Trentman T, Vaisman J, Ordia J, Weber P, Deer T, Levy R, Diaz RL, Washburn SN, Mekhail N (2012) Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia 32:1165–1179PubMed

85.

Reed KL, Black SB, Banta CJ 2nd, Will KR (2010) Combined occipital and supraorbital neurostimulation for the treatment of chronic migraine headaches: initial experience. Cephalalgia 30:260–271PubMed

86.

Reed KL, Will KR, Conidi F, Bulger R (2015) Concordant occipital and supraorbital neurostimulation therapy for hemiplegic migraine; initial experience; a case series. Neuromodulation 18:297–303 (discussion 304)PubMedPubMedCentral

87.

Bartsch T, Pinsker MO, Rasche D, Kinfe T, Hertel F, Diener HC, Tronnier V, Mehdorn HM, Volkmann J, Deuschl G, Krauss JK (2008) Hypothalamic deep brain stimulation for cluster headache: experience from a new multi-case series. Cephalalgia 28:285–295PubMed

88.

May A, Goadsby PJ (2001) Hypothalamic involvement and activation in cluster headache. Curr Pain Headache Rep 5:60–66PubMed

89.

Franzini A, Ferroli P, Leone M, Broggi G (2003) Stimulation of the posterior hypothalamus for treatment of chronic intractable cluster headaches: first reported series. Neurosurgery 52:1095–1099 (discussion 1099–1101)PubMed

90.

Leone M, Franzini A, Broggi G, Bussone G (2003) Hypothalamic deep brain stimulation for intractable chronic cluster headache: a 3-year follow-up. Neurol Sci 24(Suppl 2):S143–S145PubMed

91.

Fontaine D, Lazorthes Y, Mertens P, Blond S, Geraud G, Fabre N, Navez M, Lucas C, Dubois F, Gonfrier S, Paquis P, Lanteri-Minet M (2010) Safety and efficacy of deep brain stimulation in refractory cluster headache: a randomized placebo-controlled double-blind trial followed by a 1-year open extension. J Headache Pain 11:23–31PubMed

92.

Piacentino M, D’Andrea G, Perini F, Volpin L (2014) Drug-resistant cluster headache: long-term evaluation of pain control by posterior hypothalamic deep-brain stimulation. World Neurosurg 81:442.e411–442.e445

Title: A new era in headache treatment
Authors: Michail Vikelis
Konstantinos C. Spingos
Alan M. Rapoport
Publication date: 01-06-2018
Publisher: Springer International Publishing
Published in: Neurological Sciences / Issue Special Issue 1/2018
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-018-3337-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A new era in headache treatment

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 1/2018

Relationship between severity of migraine and vitamin D deficiency: a case-control study

OnabotulinumtoxinA for chronic migraine: a real-life Italian multicenter experience

Can the app HeadApp!© be useful in migraine epidemiology? A proposal of a digital algorithm for migraine criteria

Secondary forms

Pain cognition in migraine: from basic neurophysiology to a behavioral paradigm

Headache due to endovascular procedures